Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLRN Acelyrin Inc
- Stocks
- Healthcare
- NASDAQ: SLRN
Price (delayed)
$2.36
Market cap
$237.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.5
Enterprise value
$169.51M
Highlights
SLRN's quick ratio has soared by 150% QoQ and by 99% YoY
The EPS has surged by 54% year-on-year
SLRN's equity is down by 30% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of SLRN
Market
Valuations
Earnings
Shares outstanding
100.71M
Market cap
$237.68M
Enterprise value
$169.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$316.26M
Net income
-$248.23M
EBIT
-$248.23M
EBITDA
-$247.48M
Free cash flow
-$298.17M
Per share
Balance sheet
Liquidity
EPS
-$2.5
EPS diluted
-$2.5
Free cash flow per share
-$3
Book value per share
$4.57
Revenue per share
$0
TBVPS
$4.95
Total assets
$491.14M
Total liabilities
$32.85M
Debt
$6.27M
Equity
$458.29M
Working capital
$454.41M
Debt to equity
0.01
Current ratio
18.1
Quick ratio
16.87
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.4%
Return on equity
-45.2%
Return on invested capital
-64.3%
Return on capital employed
-53.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLRN stock price
How has the Acelyrin stock price performed over time
Intraday
-4.07%
1 week
-8.17%
1 month
8.51%
1 year
-51.64%
YTD
-24.84%
QTD
-4.45%
Financial performance
How have Acelyrin's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$316.26M
Net income
-$248.23M
Gross margin
N/A
Net margin
N/A
SLRN's net income is up by 35% year-on-year and by 6% since the previous quarter
Acelyrin's operating income has increased by 25% YoY and by 6% QoQ
Price vs fundamentals
How does SLRN's price correlate with its fundamentals
Growth
What is Acelyrin's growth rate over time
Valuation
What is Acelyrin stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 54% year-on-year
The stock's price to book (P/B) is 42% less than its last 4 quarters average of 0.9
SLRN's equity is down by 30% year-on-year and by 13% since the previous quarter
Efficiency
How efficient is Acelyrin business performance
Acelyrin's return on invested capital has surged by 57% YoY and by 3.5% QoQ
Acelyrin's return on equity has increased by 39% YoY but it has decreased by 2.5% QoQ
SLRN's return on assets is up by 29% year-on-year but it is down by 3.6% since the previous quarter
Dividends
What is SLRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLRN.
Financial health
How did Acelyrin financials performed over time
The current ratio has soared by 153% QoQ and by 109% YoY
SLRN's quick ratio has soared by 150% QoQ and by 99% YoY
Acelyrin's debt is 99% less than its equity
SLRN's equity is down by 30% year-on-year and by 13% since the previous quarter
Acelyrin's debt has decreased by 4.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.